Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.31 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | STAT1 | P42224 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381995 | 0.73 | ITGB2 (0.46) | LMNAGAASMN1; SMN2 | |
| SCHEMBL7292136 | 0.72 | FABP6 (0.38) | FABP6HTR2CADRA2AMAOBAKR1B1 | |
| SCHEMBL1893922 | 0.71 | — | — | |
| SCHEMBL25247539 | 0.68 | MAPT (0.35) | FABP6HTR2CADRA2AAKR1B1MAPT | |
| SCHEMBL30487410 | 0.68 | MAPT (0.35) | FABP6HTR2CADRA2AAKR1B1MAPT | |
| SCHEMBL2924947 | 0.68 | CTNNB1 (0.53) | FABP6MAOBMAPTCTNNB1NPC1 | |
| SCHEMBL30507863 | 0.65 | CTNNB1 (0.46) | FABP6MAOBMAPTCTNNB1NPC1 | |
| SCHEMBL4150416 | 0.64 | STS (0.49) | FABP6HTR2C | |
| SCHEMBL8342110 | 0.63 | MAPT (0.43) | FABP6AKR1B1MAPTAKR1B10AKR1A1 | |
| SCHEMBL30410306 | 0.63 | MAPT (0.43) | FABP6AKR1B1MAPTAKR1B10AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4818110-B2 | — | — | 2011-11-16 | — | — | JP | claimed |
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | claimed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | claimed |
| EP-1651621-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | claimed |
| WO-2005016896-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | claimed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | claimed |
| US-7947833-B2 | methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds CCK2 modulators are disclosed by sulfonylation | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7563895-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1651621-B1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-06 | — | — | EP | disclosed |
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | ALLISON BRETT D | 2008-03-27 | — | — | US | disclosed |
| US-7304051-B2 | Quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-7288651-B2 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-30 | — | — | US | disclosed |
| EP-1651622-B1 | PROCESS FOR THE PREPARATION OF 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1651621-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-03 | — | — | EP | disclosed |
| US-20050043310-A1 | Preparation of quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005016896-A1 | 2- (QUINOXALIN-5-YLSULFONYLAMINO) -BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038032-A1 | Quinoxaline compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103300-A1 | PREPARATION OF QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | FABP6 22/4885HTR2C 48/4885ADRA2A 874/4885 |
| US-20050043310-A1 | Preparation of quinoxaline compounds | CCKAR, CCKBR, GIPR | FABP6 22/4885HTR2C 48/4885ADRA2A 874/4885 |
| US-20050038032-A1 | Quinoxaline compounds | CCKAR, CCKBR, GIPR | FABP6 9/4885HTR2C 66/4885ADRA2A 1494/4885 |
| US-20080076918-A1 | QUINOXALINE COMPOUNDS | CCKAR, CCKBR, GIPR | FABP6 9/4885HTR2C 66/4885ADRA2A 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.